{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-031971","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.284822+00:00","generated_at":"2026-06-08T03:51:17.064233+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Reviva reports Q3 loss of $10.5M; Phase 3 brilaroxazine trial meets all endpoints","bullets":["Phase 3 RECOVER trial met primary endpoint: 10.1-point PANSS reduction for 50 mg brilaroxazine vs placebo at week 4 (p<0.001).","Net loss for Q3 2023 of $10.5M ($0.44/share) vs $3.5M loss ($0.18/share) in Q3 2022.","Cash of $5.0M as of Sep 30, 2023, down from $18.5M at Dec 31, 2022.","Anticipated milestones: OLE data Q4 2024; RECOVER-2 initiation Q1 2024; NDA submission 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-031971","json":"https://secwatch.observer/filing/0001437749-23-031971.json","markdown":"https://secwatch.observer/filing/0001437749-23-031971.md","text":"https://secwatch.observer/filing/0001437749-23-031971.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923031971/0001437749-23-031971-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923031971/rvph20231109c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:51:17.064233+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"017a2cf5e8de798e9c1a878fb1c304bb2854e8d0","claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported third quarter ended September 30, 2023 results: net income approximately $10.5 million, EPS ($0.44) per share.","evidence_excerpt":"The Company reported a net loss of approximately $10.5 million, or ($0.44) per share, for the three months ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923031971/0001437749-23-031971-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"approximately $10.5 million"},{"label":"EPS","value":"($0.44) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}